Jalal is a Holman Research Pathway Resident in the Department of Radiation Oncology. His work is focused on targeting the tumor microenvironment to improve anti-tumor immune responses by Chimeric Antigen Receptor (CAR) T cells.
Fundings : Lung Cancer Research Foundation and the American Society for Clinical Oncology
Pauline is a postdoctoral fellow from France. During her PhD in Immunology, she characterized the dynamics and functions of monocytes and macrophages during inflammation and their role in response to chemotherapy in lung metastasis. She is currently working on the impact of myeloid cells in the mechanism of resistance to cancer immunotherapy revealed by the combination of single-cell RNA sequencing (CITE-seq) and multiplex imaging (MIBI).
Fundings : Human Frontiers Science Program
Assaf Magen, Ph.D., is a computational biologist studying the contribution of phagocytes to tumor development in liver and lung cancers by developing analytical strategies to mine single-cell genomics and multiplex imaging data. During his doctoral work, he identified novel subsets of immune cells and their prognostic value in murine and human tumors. He is currently working on characterizing the crosstalk between immune, malignant and stromal cells, and how their interactions may affect hepatocellular carcinoma development and patient response to immunotherapy. In addition, he is interested in identifying epigenetic programs involved in myeloid cell differentiation and plasticity during tumor development.
Samarth received his Ph.D. in 2019 under Dr. David DeNardo at Washington University in St. Louis, where he worked on T cell immune surveillance dysfunction in pancreatic cancer. In the Merad Lab, Samarth is interested in understanding global immune interactions across different tumor contexts, focusing on dendritic cell dysfunction over tumor progression. He will utilize high-dimensional tools in mouse models and human patient samples to study the impact of tumor microenvironment and cell-intrinsic signaling on the function of proximal myeloid cells.
Fundings : The National Cancer Institute F99/K00 Predoctoral-to-Postdoctoral Transition Fellowship
Matthias is an MD in training for Hematology and Oncology from Düsseldorf / Germany. During his previous research in Zurich / Switzerland he was working on clonal hematopoiesis and Langerhans cell histiocytosis. As a postdoctoral fellow, he is now further studying the pathophysiology of Langerhans cell histiocytosis and aspects of senescence in solid tumors.
Fundings : Swiss National Science Foundation and Swiss Cancer League
Meriem is a postdoctoral fellow from Algeria. She obtained her PhD in immunology at the University of Paris (France). Now, in her postdoctoral fellowship, she will participate in the research study, which focuses on the innate immune system to develop novel therapies against cancer. In particular, she will study the biology of dendritic cells and macrophages that reside in cancer tissues to understand whether specific defects in these cells contribute to disease pathogenesis and whether dendritic cells and macrophage defects could be restored.
Raphael is a postdoctoral fellow from France. He completed his PhD in the laboratory of Dr. Marc Dalod at the Centre d’Immunologie de Marseille-Luminy on the role of type 1 conventional dendritic cells in breast cancer immunosurveillance. In the Merad lab, Raphael disentangles the spatial functional contribution of dendritic cells to tumor specific immunity in the tumor microenvironment versus the tumor draining lymph nodes in mice and patients.
Nelson obtained his PhD from Harvard University under Drs. Michael Brenner and Lydia Lynch. There, he studied the role of adipose tissue-resident lymphocytes in regulating metabolic homeostasis. In the Merad Lab, he continues to examine the relationship between metabolism and myeloid cell biology, particularly in the contexts of cancer and inflammation.
Maxime is a postdoctoral fellow who is part of both the Merad Lab and the Brown Lab. He is taking advantage of the Jedi mice (developed by the Brown laboratory) to study the mechanisms of cytotoxic CD8+ T cell (CTLs)-mediated tumor regression in vivo. He is particularly interested in the interactions between CTLs and cancer-initiating cells.
Fundings: Belgian American Education Foundation
Alfonso is a postdoctoral fellow from Madrid, Spain. During his PhD studies in the University of Navarra (Pamplona, Spain), he investigated the role type 1 conventional dendritic cells play in cancer immunity. In conjunction with Brian Brown’s lab, he is currently working on the development of novel myeloid cell-targeted therapies in the context of cancer immunotherapy.
Gurkan received his master’s degree in molecular biology and genetics from Koc University (Istanbul, Turkey) and his doctorate in oncological sciences from the University of Utah School of Medicine. He joined the Merad and the Brown labs at Mount Sinai to study the role of cancer genetics in tumor immunity. He is fascinated by the nature of the complex interactions between cancer cells and immune cells. He thinks that a better understanding of the incredibly dynamic co-evolution of cancer cells and the immune system will eventually make most cancers if not all manageable diseases.
Funding: The National Cancer Institute